Last reviewed · How we verify
mohamed bouchoucha — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| placebo based quadriple therapy | placebo based quadriple therapy | marketed | ||||
| metronidazole based quadriple therapy | metronidazole based quadriple therapy | marketed | Antibiotic combination therapy | Helicobacter pylori DNA and bacterial cell integrity | Gastroenterology / Infectious Disease |
Therapeutic area mix
- Gastroenterology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Mackay Memorial Hospital · 1 shared drug class
- Takeda · 1 shared drug class
- University of Valencia · 1 shared drug class
- West Virginia University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for mohamed bouchoucha:
- mohamed bouchoucha pipeline updates — RSS
- mohamed bouchoucha pipeline updates — Atom
- mohamed bouchoucha pipeline updates — JSON
Cite this brief
Drug Landscape (2026). mohamed bouchoucha — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mohamed-bouchoucha. Accessed 2026-05-16.